Case series analysis stratified by NRT formulation and date of prescription
| Myocardial infarction analysis | Stroke analysis | |||||
|---|---|---|---|---|---|---|
| Events | Relative incidence | 95% CI | Events | Relative incidence | 95% CI | |
| Patch users | ||||||
| 1–56 days before NRT | 53 | 4.10 | 3.05 to 5.50 | 23 | 2.67 | 1.73 to 4.12 |
| 1–56 days after NRT | 17 | 1.30 | 0.80 to 2.12 | 13 | 1.41 | 0.80 to 2.48 |
| Gum, lozenge, microtablet users | ||||||
| 1–56 days before NRT | 19 | 8.09 | 4.86 to 13.47 | 11 | 6.28 | 4.07 to 216.6 |
| 1–56 days after NRT | 2 | 0.79 | 0.19 to 3.24 | 1 | 0.54 | 0.07 to 3.94 |
| Inhaler and nasal spray users | ||||||
| 1–56 days before NRT | 16 | 16.64 | 8.93 to 31.01 | 5 | 8.35 | 2.95 to 23.62 |
| 1–56 days after NRT | 2 | 2.01 | 0.48 to 8.48 | 1 | 1.74 | 0.22 to 13.39 |
| Prescription before April 2001 | ||||||
| 1–56 days before NRT | 19 | 4.27 | 2.64 to 6.90 | 12 | 4.51 | 2.53 to 8.36 |
| 1–56 days after NRT | 5 | 1.04 | 0.42 to 2.55 | 0 | ||
| Prescription after April 2001 | ||||||
| 1–56 days before NRT | 69 | 6.07 | 4.62 to 7.97 | 27 | 3.07 | 2.04 to 4.62 |
| 1–56 days after NRT | 16 | 1.38 | 0.83 to 2.30 | 15 | 1.62 | 0.51 to 2.77 |